pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
The primary function of pigments in plants is photosynthesis, which uses the green pigment chlorophyll along with several red and yellow pigments that help to capture as much light energy as possible, the other pigments ic carotenoids. Pigments are also an important factor in attracting insects to flowers to encourage pollination. Plant pigments include a variety of different kinds of molecule, including porphyrins, carotenoids, anthocyanins and betalains. All biological pigments selectively absorb certain wavelengths of light while reflecting others. The light that is absorbed may be used by the plant to power chemical reactions, while the reflected wavelengths of light determine the color the pigment will appear to the eye.
In a scientific research study or clinical trial, a flaw in the study design or the method of collecting or interpreting information. Biases can lead to incorrect conclusions about what the study or clinical trial showed. (NCI) When a point of view prevents impartial judgment on issues relating to the subject of that point of view. In clinical studies, bias is controlled by blinding and randomization (NLM) The systematic tendency of any factors associated with the design, conduct, analysis and evaluation of the results of a clinical trial to make the estimate of a treatment effect deviate from its true value. Bias introduced through deviations in conduct is referred to as 'operational' bias. The other sources of bias listed above are referred to as 'statistical'. (ICH E9) Bioavailable
People with high levels of factor VIII are at increased risk for deep vein thrombosis and pulmonary embolism. Copper is a required cofactor for factor VIII and copper deficiency is known to increase the activity of factor VIII. Factor VIII is on the World Health Organization's List of Essential Medicines.
== Applications == Ion exchange is widely used in the food and beverage industry, hydrometallurgy, metals finishing, chemical, petrochemical, pharmaceutical technology, sugar and sweetener production, ground- and potable-water treatment, nuclear, softening, industrial water treatment, semiconductor, power, and many other industries. A typical example of application is preparation of high-purity water for power engineering, electronic and nuclear industries; i.e. polymeric or inorganic insoluble ion exchangers are widely used for water softening, water purification, water decontamination, etc. Ion exchange is a method widely used in household filters to produce soft water for the benefit of laundry detergents, soaps, and water heaters. This is accomplished by exchanging divalent cations (such as calcium Ca2+ and magnesium Mg2+) with highly soluble monovalent cations (e.g., Na+ or H+) (see water softening). Another application for ion exchange in domestic water treatment is the removal of nitrate and natural organic matter. In domestic filtration systems ion exchange is one of the alternatives for water softening in households along with reverse osmosis (RO) membranes. Compared to RO membranes, ion exchange requires repetitive regeneration when inlet water is hard (has high mineral content). Industrial and analytical ion-exchange chromatography is another area to be mentioned. Ion-exchange chromatography is a chromatographical method that is widely used for chemical analysis and separation of ions.
Head of Change and Labs, Information and Digital Directorate, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Dr. Rosemary Joy Trevelyan. Director, The Tropical Biology Association. For services to Environmental Science and International Conservation. Pamela Vipond. Deputy Director, Olympic Solidarity, the International Olympic Committee. For services to Sport. Paul Walker. Co-Founder and Co-Director, Wildtracks, Belize. For services to Conservation and Biodiversity in Belize. Zoe Elizabeth Walker. Co-Founder and Co-Director, Wildtracks, Belize. For services to Conservation and Biodiversity in Belize. David Justin Warmback. Honorary Consul, Durban, South Africa. For services to British Nationals in South Africa. Christopher Michael Wicker. President and Trustee, Hertford British Hospital Charity; Secretary General, Save the Valletta Skyline Appeal. For services to Charity and to British Nationals in France and Malta. Steven Leonard Williams. Kyaninga Child Development Centre and Kyaninga Forest Foundation, Uganda. For services to Disabled Children and Local Communities in Western Uganda.
Sources: en.wikipedia.org
Mass change = (unbound system calculated mass) − (measured mass of system) e.g. (sum of masses of protons and neutrons) − (measured mass of nucleus) After a nuclear reaction occurs that results in an excited nucleus, the energy that must be radiated or otherwise removed as binding energy in order to decay to the unexcited state may be in one of several forms. This may be electromagnetic waves, such as gamma radiation; the kinetic energy of an ejected particle, such as an electron, in internal conversion decay; or partly as the rest mass of one or more emitted particles, such as the particles of beta decay. No mass deficit can appear, in theory, until this radiation or this energy has been emitted and is no longer part of the system. When nucleons bind together to form a nucleus, they must lose a small amount of mass, i.e. there is a change in mass to stay bound. This mass change must be released as various types of photon or other particle energy as above, according to the relation E = mc2. Thus, after the binding energy has been removed, binding energy = mass change × c2. This energy is a measure of the forces that hold the nucleons together. It represents energy that must be resupplied from the environment for the nucleus to be broken up into individual nucleons. For example, an atom of deuterium has a mass defect of 0.0023884 Da, and its binding energy is nearly equal to 2.23 MeV. This means that energy of 2.23 MeV is required to disintegrate an atom of deuterium.
=== Industrial === Historically, DNP has been used as an antiseptic and as a non-selective bioaccumulating pesticide. DNP was particularly useful as a herbicide alongside other closely related dinitrophenol herbicides like 2,4-dinitro-o-cresol (DNOC), dinoseb and dinoterb. Since 1998 DNP has been withdrawn from agricultural use. Currently, there are no actively registered pesticides containing DNP in the United States or Europe. Dinoseb is used industrially as a polymerisation inhibitor during styrene production. In 2023, the Home Office said it could not determine any legitimate industrial uses for DNP in the United Kingdom. It is a chemical intermediate in the production of sulfur dyes, wood preservatives and picric acid. A precursor to 2,4,6-trinitrotoluene (TNT), DNP has also been used to make photographic developers and explosives. DNP is classified as an explosive in the United Kingdom and the United States.
Dyck, Peter J.; Overland, Carol J.; Low, Phillip A.; Litchy, William J.; Davies, Jenny L.; Dyck, P. James B.; O'Brien, Peter C. (August 2010). "Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial: Cl vs. NPhys Trial". Muscle & Nerve. 42 (2): 157–164. doi:10.1002/mus.21661. PMC 2956592. PMID 20658599. Vitale, G.I.; Quatrale, R.P.; Giles, P.J.; Birnbaum, J.E. (July 1986). "Electrical field stimulation of isolated primate sweat glands". British Journal of Dermatology. 115 (1): 39–47. doi:10.1111/j.1365-2133.1986.tb06218.x. PMID 3524654. S2CID 23529777. Freedman, Barry I.; Bowden, Donald W.; Smith, Susan Carrie; Xu, Jianzhao; Divers, Jasmin (January 2014). "Relationships between electrochemical skin conductance and kidney disease in Type 2 diabetes". Journal of Diabetes and Its Complications. 28 (1): 56–60. doi:10.1016/j.jdiacomp.2013.09.006. PMC 3877197. PMID 24140119. Ramachandran, Ambady; Moses, Anand; Shetty, Samith; Thirupurasundari, Chandragiri Janakiraman; Seeli, Abraham Catherin; Snehalatha, Chamukuttan; Singvi, Sunil; Deslypere, Jean-Paul (June 2010). "A new non-invasive technology to screen for dysglycaemia including diabetes". Diabetes Research and Clinical Practice. 88 (3): 302–306. doi:10.1016/j.diabres.2010.01.023. PMID 20188429. Raisanen, Anu; Eklund, Jyrki; Calvet, Jean-Henri; Tuomilehto, Jaakko (June 2014). "Sudomotor Function as a Tool for Cardiorespiratory Fitness Level Evaluation: Comparison with Maximal Exercise Capacity". International Journal of Environmental Research and Public Health.
Let us imagine how many people would die if war breaks out. There are 2.7 billion people in the world, and a third could be lost. If it is a little higher it could be half ... I say that if the worst came to the worst and one-half dies, there will still be one-half left, but imperialism would be razed to the ground and the whole world would become socialist. After a few years there would be 2.7 billion people again.
Sources: en.wikipedia.org
=== Deprotonation === Alkyl nitriles are sufficiently acidic to undergo deprotonation of the C-H bond adjacent to the C≡N group. Strong bases are required, such as lithium diisopropylamide and butyl lithium. The product is referred to as a nitrile anion. These carbanions alkylate a wide variety of electrophiles. Key to the exceptional nucleophilicity is the small steric demand of the C≡N unit combined with its inductive stabilization. These features make nitriles ideal for creating new carbon-carbon bonds in sterically demanding environments.
is the Avogadro constant Assuming concentration gradient is constant for all newly applied topical drugs and the temperature is constant (normal body temperature: 37 °C), the viscosity and radius of the drug determine the flux of diffusion. The higher the viscosity or the larger the radius of the drug is, the lower the diffusion flux of the drug is.
== Toxicity == Modern medicine finds that mercury is inherently toxic, and that its toxicity is not due to the presence of impurities. While mercury does have anti-microbial properties, and used to be widely used in Western medicine, its toxicity does not warrant the risk of using it as a health product in most circumstances. The Centers for Disease Control and Prevention have also reported a number of cases of lead poisoning associated with Ayurvedic medicine. Other incidents of heavy metal poisoning have been attributed to the use of rasashastra compounds in the United States, and arsenic has also been found in some of the preparations, which have been marketed in the United States under trade names such as "AyurRelief", "GlucoRite", "Acnenil", "Energize", "Cold Aid", and "Lean Plus". Ayurvedic practitioners claim that these reports of toxicity are due to failure to follow traditional practices in the mass production of these preparations for sale, however there is ample evidence of mercury and lead toxicity. The government of India has ordered that Ayurvedic products must specify their metallic content directly on the labels of the product; however, M. S. Valiathan noted that "the absence of post-market surveillance and the paucity of test laboratory facilities [in India] make the quality control of Ayurvedic medicines exceedingly difficult at this time."
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.